retatrutide – Medxy AI

Retatrutide: A Promising Triple Hormone Receptor Agonist for Obesity Management and Related Comorbidities

By MedXY 11/12/2026

Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, demonstrates marked weight loss and improvement in knee osteoarthritis pain and obstructive sleep apnea in adults with obesity in a phase 3 trial.

Diabetes & Endocrinology news

Retatrutide: A Breakthrough Triple Agonist for Obesity and Type 2 Diabetes Management

By MedXY 10/15/2026

Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, significantly reduces bodyweight and improves glycemic control in adults with obesity and type 2 diabetes, showing promising efficacy and a manageable safety profile in the phase 3 TRIUMPH-2 trial.

Cardiology Diabetes & Endocrinology news

Retatrutide Produces Broad Favorable Shifts in Fatty Acid Oxidation and Insulin Resistance Biomarkers in Obesity With or Without Type 2 Diabetes

By MedXY 05/16/2026

Post-hoc metabolomic and lipidomic analyses from two phase 2 trials suggest retatrutide favorably remodels metabolic pathways linked to fatty acid oxidation, insulin resistance, and triglyceride composition in obesity, with and without type 2 diabetes.

Clinical Updates Diabetes & Endocrinology news Specialties

Retatrutide in Type 2 Diabetes and MASLD: Integrative Evidence on Body Composition and Liver Fat Reduction

By MedXY 08/02/2025

Retatrutide, a triple hormone receptor agonist, significantly reduces body fat and liver fat in patients with type 2 diabetes and MASLD, with a favorable safety profile and preservation of lean mass.